Go Pro
→ U.S. Rival Just Raised the Stakes for This Quiet Company (From i2i Marketing Group, LLC) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$74.82
0.0%		$80.80
$48.78
▼
$93.42
$14.61B0.972.88 million shs597,328 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$65.21
-2.0%		$62.75
$49.26
▼
$70.98
$12.63B0.242.06 million shs474,978 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$58.80
-0.4%		$55.16
$33.76
▼
$59.72
$14.60B0.422.65 million shs641,302 shs
RayzeBio, Inc. stock logo
RYZB
RayzeBio
$62.49
$62.47
$17.95
▼
$62.51
$3.74BN/A553,592 shsN/A
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-2.28%-11.41%+10.58%+40.20%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+1.99%+4.26%+14.89%+15.16%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.00%+9.14%+11.36%+55.78%
RayzeBio, Inc. stock logo
RYZB
RayzeBio
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$74.82
0.0%		$80.80
$48.78
▼
$93.42
$14.61B0.972.88 million shs597,328 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$65.21
-2.0%		$62.75
$49.26
▼
$70.98
$12.63B0.242.06 million shs474,978 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$58.80
-0.4%		$55.16
$33.76
▼
$59.72
$14.60B0.422.65 million shs641,302 shs
RayzeBio, Inc. stock logo
RYZB
RayzeBio
$62.49
$62.47
$17.95
▼
$62.51
$3.74BN/A553,592 shsN/A
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-2.28%-11.41%+10.58%+40.20%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+1.99%+4.26%+14.89%+15.16%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.00%+9.14%+11.36%+55.78%
RayzeBio, Inc. stock logo
RYZB
RayzeBio
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$101.5335.33% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.74
Moderate Buy$89.1736.36% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.07-15.52% Downside
RayzeBio, Inc. stock logo
RYZB
RayzeBio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RYZB, BBIO, EXEL, and BMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/1/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$96.00 ➝ $110.00
9/1/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$88.00 ➝ $90.00
9/1/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/31/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$104.00 ➝ $105.00
8/31/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$59.00 ➝ $60.00
8/26/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$88.00
8/19/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$98.00
8/18/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$54.00
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M29.21N/AN/A($10.77) per share-6.97
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B3.93$2.80 per share23.32$31.68 per share2.06
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.33$3.04 per share19.49$8.06 per share7.35
RayzeBio, Inc. stock logo
RYZB
RayzeBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37176.7712.000.482.14%5.32%3.69%10/26/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.6415.931.7635.33%42.17%31.76%11/3/2026 (Estimated)
RayzeBio, Inc. stock logo
RYZB
RayzeBio
-$68.60MN/AN/AN/AN/AN/AN/AN/AN/A

Latest RYZB, BBIO, EXEL, and BMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
RayzeBio, Inc. stock logo
RYZB
RayzeBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
RayzeBio, Inc. stock logo
RYZB
RayzeBio
N/A
31.85
31.85

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
RayzeBio, Inc. stock logo
RYZB
RayzeBio
N/A

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
RayzeBio, Inc. stock logo
RYZB
RayzeBio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
RayzeBio, Inc. stock logo
RYZB
RayzeBio
8859.92 millionN/ANo Data

Recent News About These Companies

Double IPOs headline this week's biotech financings
March 23, 2025  |  pharmaphorum.comP
Esports Entertainment (OTC:GMBL) Stock Quotes, Forecast and News Summary
October 4, 2024  |  benzinga.comhttps://www.benzinga.com/quote/GMBL
NextPlay Technologies (OTC:NXTP) Stock Quotes, Forecast and News Summary
October 4, 2024  |  benzinga.comhttps://www.benzinga.com/quote/NXTP
LeddarTech Holdings (NASDAQ:LDTC) Stock Quotes, Forecast and News Summary
October 3, 2024  |  benzinga.comhttps://www.benzinga.com/quote/LDTC
BMS strikes again, with $4.1bn RayzeBio takeover bid
August 2, 2024  |  pharmaphorum.comP
Getting In on This "Macro-Trend"
May 10, 2024  |  nasdaq.comhttps://www.nasdaq.com/articles/getting-in-on-this-macro-trend
BMY Feb 2024 37.000 put
February 13, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/BMY240216P00037000/chart
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
February 12, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/bristol-myers-squibb-rayzebio-announce-115900700.html?.tsrc=rss
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates RYZB, VIA, CPE, FGH
January 10, 2024  |  bakersfield.comB
Investing in RayzeBio Inc. (RYZB): What You Must Know
January 2, 2024  |  knoxdaily.comK
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
December 31, 2023  |  businesswire.comhttp://www.businesswire.com/news/home/20231231435193/en/RAYZEBIO-INVESTOR-ALERT-by-the-Former-Attorney-General-of-Louisiana-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-RayzeBio-Inc.---RYZB/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhB__5V88nVkCXMuGGyEbefTrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3m2lReS6bg93GNjCK4R7VQTZzC18GwA9IvHQuvfNZfs7g==
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
December 31, 2023  |  businesswire.comhttps://www.businesswire.com/news/home/20231231435193/en/RAYZEBIO-INVESTOR-ALERT-by-the-Former-Attorney-General-of-Louisiana-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-RayzeBio-Inc.---RYZB
RayzeBio just downgraded at JPMorgan, here's why
December 28, 2023  |  realmoney.thestreet.comhttps://realmoney.thestreet.com/rec-downgrade/ryzb-bmy-rayzebio-just-downgraded-at-jpmorgan-heres-why
RBC says Bristol Myers/RayzeBio deal validates Fusion 's approach
December 28, 2023  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/rbc-says-bristol-myersrayzebio-deal-validates-fusion-s-approach/ar-AA1m3HQW
RayzeBio downgraded to Hold from Buy at Truist
December 28, 2023  |  realmoney.thestreet.comhttps://realmoney.thestreet.com/rec-downgrade/ryzb-bmy-fusn-rayzebio-downgraded-to-hold-from-buy-at-truist
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
December 26, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/m/f052a723-31d9-3ef8-aa93-ccb1fe58fef4/bristol-myers%27-%244.1-billion.html?.tsrc=rss
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 26, 2023  |  msn.comhttps://www.msn.com/en-us/money/news/why-rayzebio-shares-are-trading-higher-by-100-here-are-other-stocks-moving-in-tuesdays-mid-day-session/ar-AA1m46If
Bristol Myers buying RayzeBio, FedEx buyback: Trending tickers
December 26, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/video/bristol-myers-buying-rayzebio-fedex-203125228.html?.tsrc=rss
Midday movers: Intel, RayzeBio, and more
December 26, 2023  |  za.investing.comhttps://za.investing.com/news/midday-movers-intel-rayzebio-and-more-432SI-2965702
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
December 26, 2023  |  benzinga.comhttps://www.benzinga.com/m-a/23/12/36385973/health-care-company-bristol-myers-squibb-announces-merger-with-rayzebio

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$74.82 -0.02 (-0.03%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$65.20 -1.33 (-1.99%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$58.80 -0.21 (-0.36%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

RayzeBio stock logo

RayzeBio NASDAQ:RYZB

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas